BioMedPartners was one of the first venture capital firms in continental Europe to focus only on life sciences, building its funds and team around Switzerland and Germany with deep ties to Roche, ETH, and the University of Basel, and its partners have personally founded and sold companies like GlycoVaxyn (to GSK) and Inositec (to Vifor Pharma). The firm has repeatedly backed specific, less obvious scientific bets—such as Claudin-1 as an anti-fibrotic target at Alentis, cancer drug resistance biology at Tolremo, and early T-cell vaccine platforms at Okairos—and its portfolio includes major exits like Tubulis (up to $5 billion Gilead deal), Cardior (Novo Nordisk), Numab/Yellow Jersey (J&J), and NBE-Therapeutics (Boehringer Ingelheim).
Investors AT THE FUND
Notable Investments
What Makes them Unique
Press & Media
No items found.
Sheets They're In
No items found.
Is this information out of date? Let us know
Popular fUNDS
Fund name
Active in
Rounds
Avg. Check
Links
.svg)
Or automatically find your investor matches
Upload your pitch deck to get your best investor matches in minutes.
Reveal the very best VCs to pitch for your startup
Get matching investors' email addresses
No ads. No catch. Free from VC Sheet.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Success. Check your email in 5 minutes.
.jpeg){kind=logo}
.png)
.jpeg)
.jpeg)
